A phase II pilot study of combination of irinotecan and cisplatin in docetaxel/cisplatin-responsive advanced non-small cell lung cancer
Latest Information Update: 02 Dec 2008
At a glance
- Drugs Irinotecan (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 11 Sep 2007 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 05 Sep 2006 New trial record.